New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
05:34 EDTABBVAbbVie submits MAAs to EMA for investigational HCV therapy
AbbVie submitted marketing authorization applications, or MAAs, to the European Medicines Agency, or EMA, seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1, or GT1, hepatitis C virus, or HCV, infection. The MAAs are supported by data from the largest all-oral, interferon-free clinical program in GT1 patients conducted to date, which consists of six Phase III studies that include more than 2,300 patients in over 25 countries.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
11:19 EDTABBVEnanta announces JAMA publication of AbbVie VIEKIRA PAK study results
Subscribe for More Information
11:04 EDTABBVAbbVie reports VIEKIRA PAK HPV/HIV co-infection study results published
Subscribe for More Information
February 20, 2015
10:33 EDTABBVBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
07:23 EDTABBVAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
February 19, 2015
12:13 EDTABBVAbbVie increases quarterly dividend 4% to 51c per share
Subscribe for More Information
February 17, 2015
18:06 EDTABBVPaulson & Co gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use